Isomorphic Labs announces strategic collaborations with two of the world’s leading pharmaceutical companies, Eli Lilly and Company and Novartis. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.
These partnerships have the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties that may result from future drug sales, and are testament to Isomorphic’s approach to drug design and the progress we are making.
“We’re thrilled to embark on this partnership and apply our proprietary technology platform, the next generation of AlphaFold, and access to massive computing power to Lilly’s development programs,” said Demis Hassabis, CEO and founder of Isomorphic Labs. “The focus we share on advancing groundbreaking drug design approaches and appreciation of state-of-the-art science makes this partnership particularly compelling.”
Isomorphic Labs operates autonomously within Alphabet Inc., with its own dedicated resources and exclusive focus on the application of AI to drug discovery. The company is reimagining the entire drug discovery process from first principles with an AI-first approach, working to build powerful new predictive and generative models of biological phenomena to anticipate how drugs will perform and design novel molecules.
👉 For more information: News – Isomorphic Labs
